BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17290105)

  • 1. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls.
    Pijnenburg YA; Janssen JC; Schoonenboom NS; Petzold A; Mulder C; Stigbrand T; Norgren N; Heijst H; Hack CE; Scheltens P; Teunissen CE
    Dement Geriatr Cogn Disord; 2007; 23(4):225-30. PubMed ID: 17290105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
    Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
    Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.
    Rosso SM; van Herpen E; Pijnenburg YA; Schoonenboom NS; Scheltens P; Heutink P; van Swieten JC
    Arch Neurol; 2003 Sep; 60(9):1209-13. PubMed ID: 12975285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
    Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
    Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Rentzos M; Paraskevas GP; Kapaki E; Nikolaou C; Zoga M; Rombos A; Tsoutsou A; Vassilopoulos D D
    J Neurol Sci; 2006 Nov; 249(2):110-4. PubMed ID: 16843497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF biomarker levels in early and late onset Alzheimer's disease.
    Bouwman FH; Schoonenboom NS; Verwey NA; van Elk EJ; Kok A; Blankenstein MA; Scheltens P; van der Flier WM
    Neurobiol Aging; 2009 Dec; 30(12):1895-901. PubMed ID: 18403055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD.
    Sjögren M; Rosengren L; Minthon L; Davidsson P; Blennow K; Wallin A
    Neurology; 2000 May; 54(10):1960-4. PubMed ID: 10822437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
    Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
    Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
    Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
    Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.